Revista da Sociedade Brasileira de Medicina Tropical
[Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Länken sparas på Urklipp
Nyckelord
Abstrakt
We treated six patients with mucosal leishmaniasis who failed to respond to glucantime (20 mg/kg/day) with ambisome (2-5 grams total dose). The daily dose was 2-3 mg/kg/day given for a minimum of 20 days. After 26-38 months of follow up, five patients were clinically cured. One relapsed after six months. No side effects of therapy were observed apart from headache after infection. Ambisome is a therapeutic option for patients with mucosal leishmaniasis unresponsive to antimonials.